AA Multiple randomized trials or meta-analyses, consistent results. How we grade →RCT · 27,564 people with atherosclerotic disease on statins
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
M Sabatine, R Giugliano, A Keech, N Honarpour, S Wiviott, S Murphy et al. New England Journal of Medicine. 2017.
- In plain language
- FOURIER: evolocumab lowered LDL cholesterol by 59% and the main composite of heart events by 15% (HR 0.85) over a median 2.2 years.
- Limits
- People with established heart disease, short follow-up. Funded by Amgen, the drug's maker.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Notes on the Blueprint protocol
- Source
- doi.org/10.1056/NEJMoa1615664 · PubMed 28304224
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.